welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggests
Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes.
The study, “Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy,” was published in the journal Neuromuscular Disorders.
DMD is an inherited childhood-onset disease characterized by mutations in the DMD gene that provides instructions for making a protein called dystrophin, located primarily in skeletal muscles used for movement and in the heart muscle. These mutations lead to progressive muscle weakness.
rareRelated
-
Bone health and osteoporosis management of the patient with Duchenne muscular dystrophyDuchenne muscular dystrophy is associate...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
Finding the Optimum Regimen for Duchenne Muscular DystrophyThe Finding the Optimum Regimen for Duch...
-
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients...PTC Therapeutics, Inc. today announced t...
-
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular DystrophyThe expanded access program will provide...
-
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)This long-term extension study is an ope...
-
Effect of Deflazacort and Prednisone Versus Placebo on Pulmonary Function in Boys with Duchenne Muscular Dystrophy W...Objective: To prospectively assess the ...
-
Developing standardized corticosteroid treatment for Duchenne muscular dystrophyDespite corticosteroids being the only t...
